{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Optimized+Background+Regimen", "query": { "intervention": "Optimized Background Regimen" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Optimized+Background+Regimen&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T04:01:59.819Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01026727", "title": "A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "MPC-4326 plus a 2-3 drug optimized background regimen (OBR)", "type": "DRUG" }, { "name": "3-4 commercially available antiretroviral drugs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myrexis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2009-11", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2010-06-14", "last_synced_at": "2026-09-04T04:01:59.819Z", "location_count": 21, "location_summary": "Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01026727" }, { "nct_id": "NCT00950859", "title": "A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "GSK1349572 (Cohort I)", "type": "DRUG" }, { "name": "GSK1349572 (Cohort II)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2009-08", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2015-12-04", "last_synced_at": "2026-09-04T04:01:59.819Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Long Beach, California • San Francisco, California + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00950859" }, { "nct_id": "NCT00056641", "title": "Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "tipranavir", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" }, { "name": "saquinavir", "type": "DRUG" }, { "name": "amprenavir", "type": "DRUG" }, { "name": "lopinavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 328, "start_date": "2003-02-18", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-12-01", "last_synced_at": "2026-09-04T04:01:59.819Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Berkeley, California • Fountain Valley, California + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00056641" }, { "nct_id": "NCT00197145", "title": "Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus I" ], "interventions": [ { "name": "GW873140", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2005-07-21", "completion_date": "2007-09-11", "has_results": true, "last_update_posted_date": "2018-11-02", "last_synced_at": "2026-09-04T04:01:59.819Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Laguna Beach", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00197145" }, { "nct_id": "NCT01568892", "title": "Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Dolutegravir 50 mg twice daily", "type": "DRUG" }, { "name": "Dolutegravir placebo twice daily", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2012-04-18", "completion_date": "2013-12-16", "has_results": true, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-09-04T04:01:59.819Z", "location_count": 25, "location_summary": "Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 21 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01568892" }, { "nct_id": "NCT00488059", "title": "A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "enfuvirtide [Fuzeon]", "type": "DRUG" }, { "name": "Optimized background ARV", "type": "DRUG" }, { "name": "Integrase inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2007-06", "completion_date": "2008-10", "has_results": true, "last_update_posted_date": "2011-07-22", "last_synced_at": "2026-09-04T04:01:59.819Z", "location_count": 41, "location_summary": "Hobson City, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more", "locations": [ { "city": "Hobson City", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00488059" }, { "nct_id": "NCT00197197", "title": "Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5/X4-Tropic Treatment-Experienced HIV-Infected Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "GW873140", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2005-07", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2011-03-29", "last_synced_at": "2026-09-04T04:01:59.819Z", "location_count": 11, "location_summary": "Los Angeles, California • Norwalk, Connecticut • Fort Lauderdale, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00197197" }, { "nct_id": "NCT02483078", "title": "Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "PRO 140", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Optimized Background Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytoDyn, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2015-10", "completion_date": "2018-07", "has_results": true, "last_update_posted_date": "2022-11-03", "last_synced_at": "2026-09-04T04:01:59.819Z", "location_count": 34, "location_summary": "Fountain Valley, California • Long Beach, California • Los Angeles, California + 24 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02483078" }, { "nct_id": "NCT01504841", "title": "Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Etravirine (ETR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": "6 Years", "sex": "ALL", "summary": "2 Months to 6 Years" }, "enrollment_count": 26, "start_date": "2013-03-14", "completion_date": "2020-08-26", "has_results": true, "last_update_posted_date": "2021-11-02", "last_synced_at": "2026-09-04T04:01:59.819Z", "location_count": 4, "location_summary": "Miami, Florida • Chicago, Illinois • The Bronx, New York", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01504841" }, { "nct_id": "NCT00254046", "title": "TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "TMC125", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 616, "start_date": "2005-11", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2014-06-20", "last_synced_at": "2026-09-04T04:01:59.819Z", "location_count": 32, "location_summary": "Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 29 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00254046" } ] }